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Introduction: The optimal trial design for assessing novel therapies in pediatric inflammatory bowel diseases (IBD) is a subject of intense ongoing global discussions and debate among the different stakeholders. However, there is a consensus that the current situation in which most medications used in children with IBD are prescribed as off- label without sufficient pediatric data is unacceptable. Shortening the time lag between adult and pediatric approval of drugs is of most importance. In this position paper we aimed to provide guidance from the global clinical research network PIBDnet for designing clinical trials in pediatric IBD in order to facilitate drug approval for children.
Methods: A writing group has been established by PIBDnet and topics were assigned to different members. After an iterative process of revisions among the writing group and one face to face meeting, all statements have reached consensus of >80% as defined a-priori. Next, all core members of PIBDnet voted on the statements, reaching consensus of >80% on all statements. Comments from the members were incorporated in the text. 
Results: The commentary includes 18 statements for guiding data extrapolation from adults, eligibility criteria to PIBD trials, use of placebo, dosing, endpoints and recommendations for feasible trials. Controversial issues have been highlighted in the text.








* What is already known about this subject: 
	Children/adolescents with IBD have often a particularly active disease requiring early biologic therapy, however access to new medication is often delayed compared to adult patients
	Clinical drug trials are more difficult to perform in children compared to adult IBD patients.
	A simple copy/past approach from RCT in adult IBD patients to children with IBD is not appropriate

* What are the new findings: 
	This is the first consensus processes of paediatric IBD experts on how to facilitate/optimize clinical drug trial designs for children with IBD
	Extrapolation from adult trials together with PK/PD studies and safety data might suffice for drugs of a class with existing approval for PIBD.
	Particular attention should be drawn to dosing studies for younger children (<30kg) since they may require higher mg/kg dosing compared to older children and adults.
	Feasibility (adapted small sample size, reduced number of invasive procedures, reduced wash-out periods prior inclusion) is a major criterion for a successful RCT.
* How might it impact on clinical practice in the foreseeable future ?
	Avoidance of foreseeable unsuccessful RCT (too many endoscopies, unrealistic large number of patients needed etc).
	New and easily attainable Endpoints for RCTs combining objective measures as well as patient experienced symptoms.
	Improvement of global collaboration among PIBD experts as well as between PIBD experts, patient/parents organisations, agencies, CROs and/or pharmaceutical industry 





The timing of drug studies in pediatric inflammatory bowel disease (IBD) has been suboptimal with most being conducted long after approval has been granted for adult IBD (Figure 1). This time-lag leads to extensive off-label use of drugs in children, often without clear guidance on appropriate dosing. This is of concern since pediatric dosing of biologics, extrapolated from studies in adults has been often shown eventually to be too low (Table 1 summarizes a subset of the important relevant randomized pediatric studies)  ADDIN EN.CITE [1, 2, 3].  





Pediatric Inflammatory Bowel disease network (PIBDnet, www.pibd-net.org (​http:​/​​/​www.pibd-net.org​)) is a network of PIBD experts over the world with particular interest and experience in clinical research, especially drug trials, for children with IBD. PIBDnet is actively conducting RCT in the field of PIBD. A steering committee formulated sub-healings to be addressed in this position paper, each addressed by 2-3 authors and iteratively reviewed for revisions over emails and one face to face meeting. The paper was then sent to the core members of PIBDnet for re-voting. A threshold for consensus was determined a-priori as >80% which has been achieved after the first round of voting (total of 29 voting experts: 26 core members of PIBDnet and 3 external experts in the authors; Appendix 1). Comments obtained during the voting process were incorporated when possible in the text.
DATA EXTRAPOLATION TO SUPPORT PEDIATRIC LABELING IN IBD 
Statements
1.	Building on prior adult randomized controlled trials (RCT), pharmacokinetics/pharmacodynamics (PK/PD) pediatric data should suffice to approve drugs that are not of new category (i.e. availability of another approved drug in children from the same class), on condition that PK/PD (i.e. exposure response) relationship is similar to adults  ADDIN EN.CITE [4](97% agreement).   
2.	Dosing and safety, however, must be demonstrated independently from adult studies and cannot be extrapolated (100% agreement).   
Extrapolating efficacy from adults to children was first proposed by the FDA in the 1994 Pediatric Labeling Rule. FDA guidance articulates the path to three regulatory outcomes: no extrapolation, full extrapolation, and partial extrapolation (https://www.fda.gov/downloads/drugs/guidances/ucm425885.pdf (​https:​/​​/​www.fda.gov​/​downloads​/​drugs​/​guidances​/​ucm425885.pdf​)). Of 166 products approved for pediatrics between 1998 and 2008, 24 relied completely upon extrapolated data and 113 utilized partial extrapolation  ADDIN EN.CITE [5]. The path to pediatric labeling for the three FDA approved IBD therapies (balsalazide, infliximab, and adalimumab) involved partial extrapolation that assumes that children have a similar disease course and response to intervention as adults but exposure-response may differ. Subsequent efficacy trials in children would then be required if no pharmacodynamic measurements are available to predict efficacy. For partial extrapolation, one efficacy trial may be sufficient. In both cases, it is vital to start enrolling into the pediatric trial shortly after the results of the adult phase-3 trial are known, even prior to full publication. This will both ensure shortening the time to pediatric labeling and increase the feasibility of the trial (see below). 
A key component for both partial and full extrapolation is prior dose selection that achieves an exposure range comparable to what has been observed in adults. PK/PD phase 2 trial designs measures the incremental benefit of increasing exposure (bioavailability) on drug response. Doses with exposures leading to mid and high effect sizes can be further assessed in a larger, controlled phase 3 study. We have learned the importance of adequate exposure of biologics for maximizing response in IBD (more important than dose), as the PK/PD of many monoclonal antibodies is not linear. Biosimilars in children may follow a different approval path, as detailed elsewhere  ADDIN EN.CITE [6]. In all cases, whether following partial or full extrapolation, a clear plan for safety monitoring must to be in place, but this does not necessarily require a randomized controlled trial. 
DOSING 
Statements
1.	Dosing in pediatric trials should acknowledge that younger children (as a general rule <~30kg but this could differ) may require higher dose per kg than older children and adults (97% agreement).   
2.	Either body surface area (BSA)-based dosing or stratified per-kg dosing (i.e. different per-kg dose in different age groups) should be considered. In either case, PK/PD dose ranging studies across all age groups are necessary, especially in the youngest (100% agreement).    
Many monoclonal antibody medications are dosed according to body weight (e.g. mg/kg), despite weight either not predicting drug clearance or, more commonly, the relationship not being proportional (i.e. the clearance reduction is not proportional to the reduction in weight). Dosing based on mg/kg therefore frequently results in lower concentrations in smaller children, and this trend increases with lower body weight [7]. For instance, weight-based dosing of steroids results in a lower drug levels than BSA-based dosing and the difference decreases proportionally up to weights of 30kg; the same has been shown with infliximab, golimumab and adalimumab in pediatric IBD  ADDIN EN.CITE [1, 2, 3, 4, 8, 9]. Simulated trough concentrations for the approved dose of infliximab are lower as weight decreases (Figure 2)  ADDIN EN.CITE [10]. Similarly, median AUC values in children aged 6 to 17 years and aged 2 to 6 years were, respectively, 20% and 40% lower than the predicated AUC for adults following administration of 5 mg/kg infliximab q8weekly [11]. Poor planning of dosing in the pediatric clinical trials has led the European Crohn’s and Colitis Organization (ECCO) and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) to recommend higher doses of adalimumab, infliximab and golimumab than those used in the pediatric trials  ADDIN EN.CITE [12]. It is thus important to include children as young as 2 years in trials but excluding those with known monogenetic IBD-like disease. 
Conversely, monoclonal antibody medications dosed based on body surface area (e.g. mg/m2) may expose smaller children to higher relative doses than adult patients [13]. Flat dosing (i.e. “one size fits all”) results in overdosing in smaller patients and under-dosing in bigger patients. For all three dose metrics (mg/kg, mg/m2 and flat dosing), the younger patients are exposed to a more significant under or overdosing. An appropriately body-size based stratified approach may overcome these limitations.
PLACEBO 
Statements
1.	No child with IBD should be managed with a known inferior treatment than routinely available. Therefore the use of placebo should be avoided in studies where the study drug has previously been shown to be superior to placebo in children and/or in adults (93% agreement). 
2.	For a new drug-category, placebo should only be used in children who have exhausted other approved therapies in pediatrics, in order to ensure genuine equipoise between available active treatments and placebo both within the clinical trial and outside (as part of clinical practice) (83% agreement).  
3.	If true equipoise exists (both within and outside the trial) placebo may be considered only when complete remission has been achieved after (open-labeled) induction therapy; “response” without remission is insufficient. Very early escape points should be planned to allow prompt treatment for children whose disease has become active (83% agreement).   
4.	Adolescents may be included in adult placebo-controlled trials on condition that the relevant standard treatments outside the trials have been exhausted to ensure equipoise of the placebo arm with the standard of care. A sufficient sample size of the adolescent subgroup must be ensured to allow meaningful conclusions for this age group (86% agreement).    

The controversy of including placebo in pediatric IBD trials has been extensively reviewed in a position paper from ESPGHAN, ECCO, PIBDnet and the Canadian Children IBD network  ADDIN EN.CITE [14] and thus only brief guiding rules are summarized herein. Placebo is easier to justify in trials of new drug classes after all pediatric approved medications have failed. Pediatric and adult IBD are so similar in terms of treatment responsiveness that therapies shown to be effective in adults cannot be considered in equipoise with placebo in children. In the same way, equipoise regarding efficacy of a particular drug is diluted after extensive off-label use. Thus industry-sponsored trials may become more ethically challenging when a time gap exists between the adult and pediatric studies. The tendency to move away from clinical outcomes to objective measures of mucosal healing also decreases dependence on placebo to prove drug efficacy, since complete mucosal healing is rarely seen with placebo treatment (~0-10% depending on the trial). 
Several scenarios can be discussed for pediatric IBD trials, particularly for new medicines:
Scenario one: generally, placebo should only be used if the child is in remission and there is a genuine equipoise between the active treatment and placebo (Table 2). This means that, in contrast to adults, after an open label induction phase only remitters and not responders should be considered for randomization to placebo or investigational drug when otherwise justified. There is no agreement on the definition of remission for this purpose but clearly complete clinical remission is the minimum standard. Well-designed and rapid escape strategies are most important in this scenario, allowing prompt treatment for children whose disease has become active. It is unacceptable to make children with active IBD wait for rescue therapy. If a placebo-controlled RCT is based on repeat endoscopic evaluations to confirm active disease (see below), feasibility will be further compromised. 
Scenario two: randomization to different dosing schemes of the investigational drug without placebo is the most often selected design in pediatric IBD trials. To obtain clinically meaningful results without the use of a placebo arm, objective measures of efficacy are indispensible, such as achievement of mucosal healing. However, repeated endoscopies are poorly accepted by children and their parents, compromising the feasibility of a trial. Objective non-invasive biomarkers of mucosal healing, such as fecal calprotectin, combined with limited number of endoscopic assessment as outlined below, markedly facilitates the realization of a RCT. An excellent way to improve the significance of clinical measures as outcome parameters is to use prospective randomized open blind end-points (PROBE), where the evaluating investigator is not aware of the allocated treatment arm.




1.	In UC, confirmation of baseline disease activity should include sigmoidoscopic evaluation especially for drugs of new category (utilizing the Mayo endoscopic subscore or the UC endoscopic index of severity (UCEIS)) (93% agreement).    
1.	In CD, baseline disease activity should include ileocolonoscopy for drugs of new categories (utilizing the Short Endoscopic Score for CD, SES-CD). Otherwise, the pediatric CD activity index (PCDAI) versions or patient reported outcome (PRO) together with an objective measure of inflammation (e.g. calprotectin or CRP) could suffice (83% agreement).    

Narrow eligibility criteria regarding age, disease severity, disease location, or previous treatments will present additional difficulties to recruitment of children. Too broad will lead to heterogeneity of included patients. In some studies, it might not be unreasonable to include children diagnosed with IBD-unclassified (IBD-U), now that standard classification of this subgroup has been validated  ADDIN EN.CITE [16]. 
Two scoring systems, the pediatric UC activity index (PUCAI) and Mayo score, have been successfully used in previous clinical trials in pediatric UC. While only the PUCAI has been validated in children, the Mayo score allows intuitive comparison with adult trials. The PUCAI correlates well with endoscopic appearance of the colonic mucosa with a concordance of ~80% [17]. For benchmarking the two scores, a PUCAI<15 points has been found to best reflect a Mayo-score defined remission (i.e. total Mayo score of ≤2 points, with no subscore >1 point) with AUROC=0.93 (95%CI 0.88-0.99), and a change in PUCAI of at least 20 points reflects a Mayo-defined response (i.e. a decrease from baseline in the total Mayo score of ≥3 points and ≥30%, with a decrease in the subscore for rectal bleeding by ≥1 point or an absolute subscore of 0 or 1) with AUROC=0.97 (0.92-1.0)  ADDIN EN.CITE [17, 18] (Figure 3).   
The European Medicines Agency (EMA) accepts using the PUCAI to screen pediatric UC patients for trials and to grade disease activity into mild, moderate or severe (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/01/WC500200026.pdf (​http:​/​​/​www.ema.europa.eu​/​docs​/​en_GB​/​document_library​/​Regulatory_and_procedural_guideline​/​2016​/​01​/​WC500200026.pdf​)). However, in trials evaluating new categories of drugs, endoscopic activity should be determined prior to randomization ensuring a Mayo endoscopic subscore of at least 2.  Neither the Mayo score nor the UCEIS have been assessed for their psychometric properties in children. The former has the advantage of being used in practice in several pediatric trials and the latter that its development has followed a much more rigorous process. More studies on the psychometric properties if the UCEIS in children are required before making it the preferred endoscopic tool. 




1.	In general, endpoints should reflect control of mucosal or transmural inflammation. The choice of the outcome measure to reflect this concept should be individualized based on the balance of accuracy and feasibility (97% agreement).    
2.	While the ideal trial design includes 3 endoscopic evaluations (prior to study entry, at the end of the induction phase, and at the end of the maintenance phase), in children, two, one and even no evaluations may be optional based on the study design, whether the drug represents a new category and the availability of prior supportive data. While three sigmoidoscopic evaluations may be feasible (e.g. in a UC trial of a drug of new category), performing 3 ileocolonoscopies in one year (as would be required in CD) is too burdensome in children. Clinical endpoints should thus be used at the end of the induction period in CD if participants continue to a maintenance phase (83% agreement).     
3.	In some trials endoscopic evaluations performed as part of clinical practice up to one month prior to screening may be acceptable at baseline if treatment has been stable (providing that photos or videos are available for confirming the results) (100% agreement).
4.	Magnetic resonance enterography (MRE) (in children >6 years of age) or bowel ultrasound should supplement colonoscopies in CD to capture transmural healing rate and location of disease outreaching endoscopy. Radiologic measures can also be used for imputing SES-CD data when ileal intubation has been unsuccessful (100% agreement).
5.	Steroid and exclusive enteral nutrition (EEN)-free remission  whether clinically (i.e. disease activity indices or PRO) or endoscopically should be the preferred endpoint, measured at more than one time-point (i.e. sustained remission). PRO’s should only be used in adjunct together with an objective measure of inflammation (e.g. CRP and calprotectin) (97% agreement).
6.	Disease activity should be captured at every visit via PCDAI or wPCDAI in CD and PUCAI in UC. The development of PRO’s should be facilitated in pediatric IBD (97% agreement).
7.	When endoscopic assessment is waived, calprotectin (e.g. level<200-300) should accompany clinical remission (in UC PUCAI<10, and in CD either wPCDAI<10 or a composite of PCDAI<10 or <7.5 without the height item) (Tables 3 and 4) (90% agreement).
The reader is referred to a detailed position paper from the pediatric committee of ECCO on selecting endpoint measures in pediatric IBD trials  ADDIN EN.CITE [22]. Recent developments in IBD have resulted in moving away from symptom-based scoring to more objective measures of inflammation, such as endoscopic appearance, inflammatory biomarkers and radiologic endpoints. However, the choice of the endpoint must carefully balance the desire to incorporate the perfect scientific endpoint (e.g. several ileocolonoscopies) with the understanding that children are much more sensitive to repeated invasive procedures and that, pragmatically, they are more difficult to organize (e.g. needing general anesthesia). 
The choice of number of endoscopic assessments (none to three) should be based on the type of the study and drug under evaluation: prior to study entry, at the end of the induction phase, at the end of the maintenance phase, or less. In addition, the US Food and Drug administration (FDA) now requires a measurement of a patient-reported outcome (PRO) as a treatment endpoint in IBD trials. PRO’s capture symptoms important to and reported directly by patients (or by an observer in children younger than 8 years of age), without interpretation by a physician. A PRO measure is distinct from disease activity indices (e.g. PCDAI and PUCAI) and from health-related quality of life instruments (e.g. IMPACT) and therefore should be captured concurrently.  
Regardless of the choice of the endpoint, steroid/EEN-free complete remission (whether clinical or endoscopic) is preferred and should be sustained over time in maintenance of remission studies. Clinical endpoints and PRO’s should be combined with indirect serum and/or fecal biomarkers of inflammation.  
Ulcerative colitis
The most widely used endoscopic scoring system in children is the Mayo subscore of 0-3 points. Other available scores include the UCEIS  ADDIN EN.CITE [23] the Ulcerative Colitis Colonoscopic Index of severity (UCCIS) [24] and the Modified Mayo Endoscopic Score (MMES); see details in the recent guidelines on endoscopic evaluation in pediatric IBD from ESPGHAN’s IBD Porto group  ADDIN EN.CITE [25]. The MMES captures the severity of inflammation in the entire colon by adding the Mayo subscores in each of the colonic segments. The expected added benefit has been recently found to be limited in adults [26] although this might differ in children who have more often pancolitis. Nonetheless, the theoretical benefit probably does not justify the large increment of invasiveness associated with a complete colonoscopy as compared with limited sigmoidoscopy. Most investigators now agree that an endoscopic subscore of 0 should be regarded as mucosal healing but a score of 1 may be considered in selected trials based in the intervention under study and the eligible baseline severity. Correlation between macroscopic and microscopic inflammation is good for Mayo 0 but not for Mayo 1, and histological remission is associated with improved long-term outcomes  ADDIN EN.CITE [27]. Histological scoring, however, cannot currently be used as a major endpoint measure because of lack of validation and limited reliability but could be considered as a secondary endpoint to support mucosal healing.
The high concordance of the PUCAI with mucosal inflammation, described above, has led the EMA but not the FDA to recommend it as a primary endpoint when endoscopic assessment is not required and for assessing disease activity at interim visits without endoscopic assessment (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/01/WC500200026.pdf (​http:​/​​/​www.ema.europa.eu​/​docs​/​en_GB​/​document_library​/​Regulatory_and_procedural_guideline​/​2016​/​01​/​WC500200026.pdf​)).  
Several other measures are important as secondary endpoints in pediatric UC. The IMPACT-III questionnaire is validated  as a disease-specific measure of health-related quality of life for children ≥9 years of age [28]. Fecal calprotectin is an important secondary outcome measure especially in visits when endoscopic assessment is not performed  ADDIN EN.CITE [29]. However, given the large variability of results and the lack of a validated cutoff for mucosal healing, fecal markers alone cannot be used as primary endpoints. The development of a pediatric PRO for pediatric UC (TUMMY-UC) is underway under the qualification program of both the FDA and the EMA and will likely be incorporated in future clinical trials.
The primary and secondary outcomes are best determined by the agent under study. For drugs that have extensive adult data on mucosal healing and are not first-in-class, endoscopic evaluation should not be a primary outcome. Pediatric-specific disease activity scores such as PUCAI should be used as a primary outcome supplemented by fecal calprotectin. Eliminating the endoscopic procedure would significantly facilitate recruitment. All pre-registration trials of drugs of a new category, however, should require steroid-free mucosal healing as their primary outcome. Endoscopic evaluation would be required at 8 to 12 weeks for induction trials and at 54 weeks for maintenance. 
Maintenance of remission trials should span at least one year in order to allow adequate time to assess relapses. A primary endpoint of relapse-free and steroid-free sustained clinical remission at both week 30 and week 54 is recommended, with an endoscopic evaluation at weeks 54 to assess for mucosal healing  ADDIN EN.CITE [22]. 
Growth is rarely impaired in UC and thus not an important outcome measure. Some degree of osteopenia is seen in 20-30% of children with UC, much less often than in CD. 

Crohn’s disease- Table 3 and 4
Multi-item measures of disease activity, a concept incorporating symptoms, signs and biomarkers have, until recently, constituted the primary endpoint in CD clinical trials. The PCDAI or its derivatives have been most often used in children  ADDIN EN.CITE [19, 30] (Tables 3 and 4). Of the shortened PCDAI versions, the weighted PCDAI (wPCDAI) best maintains validity, whilst demonstrating greater feasibility and responsiveness to short term change, as needed in induction trials  ADDIN EN.CITE [20].  Both versions however have only fair correlations with endoscopic appearance judged by the SES-CD (r=0.33-0.45)  ADDIN EN.CITE [31].
Given the discrepancy between symptoms and presence of active intestinal inflammation, assessment of mucosal healing via complete ileocolonoscopy has emerged as an important clinical trial endpoint also in pediatric CD trials. The performance characteristics of the most commonly used endoscopic indices, CD Endoscopic Index of Severity (CDEIS) [32], its simpler derivative, the Simple Endoscopic Score for CD (SES-CD)  ADDIN EN.CITE [33], and the Rutgeerts post-operative endoscopic score, were recently critically evaluated in adults  ADDIN EN.CITE [34]. Mucosal healing should be defined as SES-CD 0-2 points or CDEIS < 6 points. Endoscopic response is defined as at least 50% reduction of baseline measure if performed but this may not be available in children when the baseline ileocolonoscopy is not mandated. 
The use of ileocolonoscopies for research purposes in children should be judicious given its invasiveness and need for general anesthesia and bowel cleansing. Thus at most one follow-up ileocolonoscopy for any given pediatric trial may be reasonable, and preferably for drugs representing new categories. 
Recently, the MINI index has been developed to reflect mucosal healing at study-visits that do not include endoscopic assessment [21]. It is weighted on fecal calprotectin and includes also CRP, ESR and the stooling item from the PCDAI. The sensitivity/specificity of a MINI<8 to reflect mucosal healing (i.e. SES-CD<3 points) was 86%/83% (area under the ROC-curve 0.92 95%CI 0.89-0.96; p<0.001); and 95% of those with a score<8 had at most mild inflammation. Although promising, more data are necessary to evaluate its utility in clinical practice and trials.   
Ileocolonoscopic examination cannot assess the proximal small intestine (L4b disease), as occurs in 10-15% of children. In addition, although the cecum is reached in over 90% of colonoscopies performed in pediatric CD, the ileum may not be intubated in up to 20-25% of cases (20% in the ImageKids study (n=240 children)  and 26% in the Eurokids registry (n=1227) [35]). In the North American RISK inception cohort, however, lower failure rates have been reported (n=1176; personal communications). Imputing the ileal subscore is mandatory to avoid biasing the results towards the milder cases, as it has been demonstrated that children without ileal intubation have more inflamed ileum and right colon. To impute the ileum by MRE: if the MaRIA score of the ileum is zero impute the ileal SES-CD as zero; otherwise apply SES-CDileum=1.145+0.169 * MaRIAileum rounded to the nearest whole number. Using this imputation resulted in a more accurate classification of mucosal healing. In the prospective ImageKids multicenter study, multi-item measures of intestinal inflammation (PICMI) and of damage (pMEDIC) are being developed and validated [36]. 
Growth and bone health are impaired in 30-50% of children with CD so measures of both should be incorporated as independent outcome measures  ADDIN EN.CITE [37]. For patients who have not completed puberty, height velocity standardized for bone age is the most sensitive measure of linear growth. However, ≥6 months’ interval is required between measures, precluding growth as an endpoint in short term induction trials.   
Despite numerous studies, no validated and ideal cutoff value for normal fecal calprotectin for use in IBD studies have been reported. In our previously published guideline on the management of Pediatric Ulcerative Colitis (part1)  ADDIN EN.CITE [12], we explored existing evidence and recommended cut-off values <100µg/g to reflect remission and values >250µg/g for mucosal inflammation. The authors of a recent systematic review  ADDIN EN.CITE [38] suggest calprotectin <250µg/g to indicate absence of inflammation and values >500µg/g mucosal ulceration. Further confirmatory studies are required before this can be definitively recommended.
 

HOW TO OPTIMIZE ENROLLMENT: SPECIFICATIONS AND PITFALLS
Statements
1.	To enhance enrollment to pediatric IBD trials (97% agreement):
a.	Set a realistic sample size for children
b.	Ensure that all children with moderate- severe disease can be rapidly treated with an effective medication, thus minimizing screening period to at most 3-5 working days, while relying mostly on local investigations 
c.	Minimize washout periods from previous drugs
d.	Minimize repeated invasive tests- make an effort to mirror routine practice as much as possible
e.	Avoid placebo and suboptimal care 
f.	Minimize time interval between the adult and pediatric trials 

Several factors make recruitment into pediatric trials more difficult than adult trials:  
	The number of prevalent IBD children is less than one tenth of the number of adult patients. The increasing number of novel drugs in the research pipeline means more competition for recruitment into trials involving the same limited pediatric population.
	Parents are frequently concerned about potential adverse events and are hesitant to perform invasive procedures.
	Pediatric trials often begin years after the drugs have received adult approval thus are available to children off-label outside the trial. Two industry-initiated pediatric trials have recently failed to meet recruitment milestones and terminated prematurely. The major issue in one study was the inclusion of placebo but the other was merely an unattractive study design unrelated to placebo. 
A feasible trial is one that mirrors routine practice as much as possible. In addition to the aforementioned potential barriers, a major preventable pitfall is avoiding a long screening period. A typical study design in biologics may require moderate-severe disease both at screening and at randomization. Adding the time to effect of the study drug, the period in which the child’s disease is active becomes unbearable and unethical. Screening period should ideally not surpass ~3-4 working days, relying on local labs for required tests (e.g. blood tests, pregnancy, stool cultures, and tuberculosis screening), and using the central labs only as a post-randomization verification. Site readers of endoscopic results are more likely to generate higher scores than the central readers, influencing results of clinical trials  ADDIN EN.CITE [39]. However, central reading should not postpone randomization and thus sponsors must ensure turnaround time of no more than 48 hours for pediatric trials. If this is not possible, then unlike in adults, central reading should be used to verify local reading; in case of a mismatch between the local and the central readers, the randomized child may be rapidly withdrawn or enrolled in a separate open label arm. 

Similarly, the washout period from previous drugs must be realistic. Asking, for instance, 8 weeks washout from previous biologics will exclude most children who poorly tolerate active disease. Individualizing the washout period by measuring trough levels and demonstrating undetectable levels can help overcome this limitation. Minimizing number of study visits and connecting via telephone or home visit may also increase recruitment. 

Increasing participants' awareness of the health problem being studied, and its potential impact on their health, can increase recruitment to clinical studies [40]. 

Nonetheless, even the best designed study should not have an overly ambitious recruitment goal. Sample sizes should be kept to the minimum that is needed to satisfy scientific rationale, using available evidence from every trial participant. Without addressing study-specific power calculations, as a very general rule a realistic sample size for a complicated pediatric RCT may be 60-120 children while a ~200 target may be still feasible for a very simple trial that mimics clinical practice. Sample size may be affected by the availability of prior convincing data from adults, choice and objectivity of endpoints, use of biomarkers demonstrating target engagement, and whether the drug is first in class. Consideration should be given to use of adaptive trial designs and approaches such as modeling/simulation, which may minimize uncertainties in assumptions of data extrapolation  ADDIN EN.CITE [41].   

FINAL NOTE






Figure 1: Years interval from approval of biologics in adults to approval in children (top two have not received pediatric indication yet and pediatric trials are still ongoing) (reproduced from  ADDIN EN.CITE [14])

Figure 2: Simulated ranges of infliximab trough concentrations following administration of 5 mg/kg at weeks 0, 2, and 6.  The boxes are stratified in 10 kg weight increments.  
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Table 1 – Summary of selected randomized clinical trials in pediatric IBD
Ulcerative colitis
Trial	Induction vs. maintenance	Number of patients	Primary Endpoint	Result
Sulfasalazine vs. olsalazine  ADDIN EN.CITE [42]	Induction (3 months)	56	"clinical improvement or asymptomatic"	79% response with sulfasalazine, 39% with olsalazine
Standard vs. low dose infliximab (T72 trial) [43]	Induction and maintenance (12 months)	60	Response (Mayo score reduction of 30% and at least 3 points with decrease in rectal bleeding subscore)	73% response at 8 weeks for induction; 38% remission at 1- year with infliximab every 8 weeks vs. 18% every 12 weeks
High vs. low dose mesalamine  ADDIN EN.CITE [44]	Induction (6 weeks)	81	Response (decrease in PUCAI by 20 points) or remission (PUCAI <10) 	56% response or remission with low dose vs. 55% with high dose
Thalidomide vs. placebo  ADDIN EN.CITE [45]	Induction (8 weeks)	26	Remission (PUCAI <10)	83% remission with thalidomide vs. 19% with placebo
Antibiotic cocktail in acute severe colitis as add-on to intravenous steroids (the PRASCO trial) [46]	Induction (during intravenous steroid treatment)	28	PUCAI score at day 5 of admission	Significantly lower PUCAI score in the antibiotics arm

Crohn’s disease
Trial	Induction vs. maintenance	Number of patients	Primary Endpoint	Result
Mercaptopurine vs. placebo [47]	Maintenance (18 months)	55	Relapse (by Harvey Bradshaw score)	9% relapse with mercaptopurine vs. 47% with placebo
Budesonide vs. prednisolone [48]	Induction (8 weeks)	81	Remission (Crohn disease activity index <150) 	71% remission rate with prednisolone vs. 55% with budesonide
Lactobacillus GG vs. placebo  ADDIN EN.CITE [49]	Maintenance (24 months)	60	Time to relapse (increase in PCDAI)	Median time to relapse 9.8 months with lactobacillus, vs. 11 months with placebo 
Standard vs. low dose infliximab (REACH)  ADDIN EN.CITE [50]	Induction and maintenance (12 months)	112	Response and remission (by PCDAI) 	88% initial response to open-label; at 1 year 56% remission with every 2 months vs. 24% with every 3 month infliximab
Standard vs. low dose adalimumab (the IMAgINE trial)  ADDIN EN.CITE [51]	Induction and maintenance (12 months)	192	Remission (PCDAI <10)	At 26 weeks 39% remission with standard dose and 28% with low dose
Thalidomide vs. placebo  ADDIN EN.CITE [52]	Induction (8 weeks)	54	Response and remission (by PCDAI)	46% remission with thalidomide vs. 12% with placebo





Table 2: Circumstances that Placebo may be incorporated in pediatric IBD trials 
Add-on to an effective treatment	As an add-on treatment to an effective treatment. Medications commenced prior to the trial and allowed to be continued after randomization cannot usually be considered “effective” since they have typically failed by the virtue of the need to start the study drug. 
No prior adult trials	In trials of drugs without prior adult approval so there is equipoise about the efficacy of the product under investigation; the use of placebo may be justified if all approved medical treatments have been exhausted and the child is in remission at the time of randomization to placebo following open label induction. Complete clinical remission should be the minimum standard. This may be utilized in a randomized withdrawal trial in which children are randomized into placebo following several months of treatment with an effective drug (rather than few weeks’ induction). 







Table 3: Endpoints in pediatric clinical trials
Type of clinical trial	Disease activity endpoint	Clinical response endpoint	Linear growth and bone formation	Endoscopic endpoints (remission; response)	Patient-reported outcome measure	HRQOL
Crohn’s disease
Short-term induction	Steroid/EEN-free clinical remission defined in Table 4	Drop in >17.5 by the wPCDAI or >12.5 by the PCDAI, or remission 	Not applicable	SES-CD (<3 points; >50% decrease) or CDEIS (<6; >50% decrease)MINI index in visits without endoscopy	TUMMY-CD when available (until then use the stool and abdominal pain items from PCDAI)	IMPACT 3
Long-term maintenance	Sustained steroid- free remission: PCDAI or wPCDAI remission at ≥2 time points (e.g. 30 and 54 months)	Not applicable	Height velocity (cm/year); serum/ urine markers of bone formation1	As above	As above	As above
Ulcerative colitis
Short-term induction	Steroid-free clinical remission, defined in Table 4 	Drop of >20 points by the PUCAI, or remission	Not applicable	Mayo endoscopic subscore of 0-3Remission: subscore=0	TUMMY-UC	IMPACT 3
Long-termMaintenance	Sustained steroid- free remission at ≥2 time points (e.g. 30 and 54 months)	Not applicable	Not applicable2	As above	As above	As above
1 DEXA scan is not responsive enough to observe a meaningful change over a year.
2 Growth is rarely impaired in ulcerative colitis in the range of ~5%, and osteopenia is less common than in Crohn’s disease




Table 4: Cutoff points of disease activity indices in pediatric IBD

	Response	Remission	Mild disease	Moderate disease	Severe disease
PCDAI	Drop of >12.5 points	<10 points or < 7.5 without the height item2	10-27.5 points	30-37.5 points	40-100 points
wPCDAI	Drop of ≥17.5 points	<12.51	12.5-40 points	42.5-57.5 points	>57.5 points
PUCAI	Drop of ≥20 points	<10 points	10-34 points	35-64 points	≥65 points

1 sensitivity and specificity 94%/93% by the PGA  ADDIN EN.CITE [20] 58%/84% by mucosal healing  ADDIN EN.CITE [31]
2 PCDAI remission was originally set at <10 points  ADDIN EN.CITE [31]; a more accurate definition is a composite of <10 points or < 7.5 without the height item  ADDIN EN.CITE [19].  

Partial list of references used for this table:  ADDIN EN.CITE [19, 20, 31]
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